Journal of Clinical Investigation Submission Guide: What to Prepare Before You Submit

The 60-70% desk rejection rate is high but reflects JCI's narrow scope: genuine translational mechanism papers with disease relevance. Papers that are excellent basic science without a convincing disease bridge get desk-rejected regardless of quality. The $0 APC is a real advantage over Nature Medicine ($11,690) and Science Translational Medicine.

Journal of Clinical Investigation is not a pure basic-science venue and not a pure clinical-outcomes venue. Editors are usually screening for:

• mechanistic explanation tied directly to disease

• enough human or disease relevance that the translational frame feels earned

• a package broad enough for physician-scientist readers

• a manuscript that already looks review-ready rather than promising but premature

That makes it a distinct target. The journal rewards the bridge between mechanism and disease, not either side alone.

JCI publishes Research Articles, Technical Advances, and Commentaries. Research Articles are the primary route for most authors.

Source: JCI Jci journal page, American Society for Clinical Investigation

Submission system is the JCI online portal at Accounts journal page. There is no APC; JCI charges a publication fee of $5,800 upon acceptance (subscription model). A sex-as-biological-variable paragraph is mandatory in the Methods section. A Supporting Data Values Excel file is required for every figure that contains statistics.

To calibrate the editorial screen, this update spot-checked recent JCI papers and in-press previews with disease-mechanism framing, including DOI examples 10.1172/JCI196374, 10.1172/JCI192328, and 10.1172/JCI200121.

Many weak JCI submissions are fit problems disguised as packaging problems. Research Articles work best when the manuscript makes one translational argument clearly: what disease problem matters, what mechanism explains it, and why the evidence package is strong enough to support that claim.

Before you worry about forms or file upload, ask:

• what disease mechanism does the paper actually resolve

• what part of the story depends on human or disease-facing evidence

• what is the first place an editor would say the claim is still too descriptive

• whether the paper would still fit Journal of Clinical Investigation if you removed the most ambitious translational language

If the answers are weak, the issue is fit, not formatting.

JCI's 60-70% desk-rejection rate reflects a focused editorial screen. Physician-scientist editors apply four questions on first read, each with a concrete pass condition.

The manuscript should make one translational argument, not several partial ones. The strongest packages usually have:

• a title that signals the disease context and the mechanistic move

• an abstract that makes the bridge visible early

• early figures that show the disease relevance and the mechanism working together

• a discussion that sounds translational without overpromising

The cover letter should:

• state the disease problem clearly

• state the mechanistic contribution clearly

• explain why those two pieces together make this a Journal of Clinical Investigation paper

Weak cover letters ask for prestige. Strong cover letters explain fit.

The first figures should make the bridge visible. If disease significance appears only late in the figure sequence or the human relevance looks like an appendix, the package weakens on first read. JCI editors evaluate whether the central translational argument is demonstrated in the opening figures, not just stated.

Before upload, the package should already look stable: the translational argument, figure order, and key controls are settled. Required elements include a Supporting Data Values Excel file for all figures containing statistics, a sex-as-biological-variable statement in the Methods section, and completed reporting checklists (CONSORT for trials, STROBE for observational studies). If these pieces are still unfinished, it is usually too early to submit.

• the disease layer is rhetorical instead of structural

• the human evidence is too light

• the mechanism is still mostly descriptive

• the translational claim outruns the figures

• the manuscript looks like two half-fit papers stitched together

• the package is still one revision cycle short of a hard editorial read

Those are not cosmetic misses. They are the real reasons the fit breaks.

Even good science often shows the mismatch in visible ways:

• the abstract sounds translational, but the figures still mainly describe patterns

• the human component is present, but it does not actually support the central claim

• the disease language is strong while the mechanism remains partial

• the paper reads like a basic paper with patient flavor rather than a true disease-mechanism bridge

That is why some respectable papers move better in a different venue.

Before anyone sends the paper to review, the package should already communicate:

• what disease mechanism is being resolved

• why the disease consequence matters

• why the human or disease-facing evidence changes the argument

• why the story belongs in Journal of Clinical Investigation rather than somewhere more basic or more clinical

If those points still require too much author explanation, the package usually is not yet doing enough work on its own.

JCI requires these at first submission:

• main manuscript file in JCI Research Article format

• cover letter establishing translational fit and disease relevance

• full names of all authors with institutional affiliations during the period when the work was performed

• responsible party / corresponding author complete contact details

• sex-as-biological-variable paragraph in the Methods section (mandatory per JCI policy)

• Supporting Data Values Excel file for every figure that contains statistics (mandatory)

• declaration of generative AI use in the Methods section specifying content, platform, version, and date of use

• data availability statement with deposition accessions where applicable

• ethics statements (animal protocols, human subjects IRB approval, informed consent)

• code availability statement for computational work

• competing interests declaration

• author contribution statement

• suggested reviewers and excluded reviewers with rationale

• for revised submissions, point-by-point response and marked-up manuscript

For JCI submissions, the most common artifact-related issue is the Supporting Data Values Excel requirement. Many groups treat this as a post-acceptance task and submit without it; JCI editors increasingly use this file to triage figure rigor during desk-screen, so missing or thin Supporting Data Values directly raises desk-rejection probability.

JCI manuscripts move through a four-stage editorial timeline. The journal's 60-70% desk-rejection rate compresses the front end of the window.

Day 0 to 3: ASCI portal intake and technical check

The portal performs an automated technical check (format compliance, declarations, Supporting Data Values file presence, sex-as-biological-variable paragraph). Editorial staff route complete submissions to a Science Editor; incomplete submissions are returned with a request to address missing elements.

Day 3 to 21: Science Editor and Deputy Editor desk-screen

A Science Editor performs the first read; manuscripts with clear translational mechanism and human relevance advance to a Deputy Editor or Associate Editor for a substantive desk-screen. The Deputy Editor decides whether the paper meets the disease-mechanism bar JCI requires (causal mechanism, human or disease-facing evidence, translational stakes). Desk-rejections at this stage cite scope, mechanism strength, or translational stakes rather than technical details.

Week 3 to 8: External peer review

Manuscripts that pass desk-screen go to 2-3 expert reviewers. Reviewer turnaround on JCI is faster than at most mid-tier biomedical journals because the Deputy Editor pre-filters heavily. The Associate Editor synthesizes reports into a first-round decision.

Week 8 to 16: Decision and revision rounds

First decisions arrive at the 6-10 week median, typically as major or minor revision. Revision cycles add 6-12 weeks. Editorial questions are addressed to the Science Editors at editors@the-jci.org. The Editor in Chief, Deputy Editors, Associate Editors, Executive Editor, and Science Editors share responsibility for editorial integrity.

• the paper is still mainly descriptive

• the disease relevance still feels argued rather than demonstrated

• the human layer is too light

• the mechanism still depends on one obvious missing step

• a more basic or more specialist journal still feels like the more honest home

• Is Journal of Clinical Investigation a Good Journal?

• How to Avoid Desk Rejection at Journal of Clinical Investigation

• Nature Medicine journal overview

• Experimental and Molecular Medicine submission guide

Before you upload, run your manuscript through a JCI translational evidence and submission readiness check to catch the issues editors filter for on first read.

Use the guide for portal, routing, and policy details; use the manuscript check for the editor-facing fit call. The review tells you whether your paper clears the Journal of Clinical Investigation fit check before upload, especially around disease relevance that lives only in the Introduction and Discussion, not in the data, mechanistic claims that read as correlational rather than causal, and human evidence added as a final panel rather than built into the argument.

Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

For manuscripts targeting the Journal of Clinical Investigation, three submission shapes reliably predict desk-screen failure among the papers we analyze.

Manusights pre-submission pattern analysis shows many desk rejections at the Journal of Clinical Investigation trace to scope or framing problems that prevent the paper from competing in this venue. The same pattern analysis often finds these cases involve insufficient methodological rigor or missing validation evidence. A related pattern is that these cases often arise from a novelty claim that outpaces the supporting data.

Disease relevance that lives only in the Introduction and Discussion, not in the data

JCI's author instructions emphasize that accepted papers must demonstrate "mechanistic understanding of disease processes relevant to human biology," and we see a recurring pattern where the experimental data are strong basic science but the disease connection appears only in framing language. Editors can identify this immediately: if removing every sentence that mentions the disease name would not change what the figures show, the translational argument has not been built into the paper.

Check disease relevance that lives only in the introduction and discussion, not in the before submitting to Journal of Clinical Investigation →

Mechanistic claims that read as correlational rather than causal

JCI editors want to see that the mechanism is tested, not just observed. We observe that papers presenting association-level evidence, genetic correlations, or expression patterns without functional validation of the proposed mechanism, consistently draw either desk rejection or a first-round revision request that cannot be addressed without substantial new experiments. Papers that include loss-of-function or gain-of-function data, genetic rescue experiments, or human disease variant validation survive the screen at a much higher rate.

Check mechanistic claims that read as correlational rather than causal before submitting to Journal of Clinical Investigation →

Human evidence added as a final panel rather than built into the argument

JCI's scope requires work that is relevant to human disease, and we observe that human data positioned as confirmatory, a single patient cohort at the end of an otherwise mouse-model paper, consistently weakens the submission even when the human data are significant. The papers that clear the editorial screen are those where the human evidence changes how the mechanism is framed, not just where it is mentioned.

SciRev author-reported data confirms JCI's approximately 45-day median to first decision for papers that pass desk review. A JCI mechanistic evidence and human disease framing check can assess whether your mechanistic evidence and human disease framing meet the journal's translational standard before you submit.

Check human evidence added as a final panel rather than built into the argument before submitting to Journal of Clinical Investigation →

Source limitations: This Journal of Clinical Investigation Submission Guide: What to Prepare Before You Submit page combines official guidance where available, public publisher or product materials, and Manusights editorial analysis for Jci; it is an independent readiness screen, not official guidance from the journal, publisher, or service. In our work, we observe that editors specifically screen Jci submissions for fit, evidence completeness, and reviewer-risk signals before the manuscript can benefit from strong prose.

How this page was created: sources used include JCI author information, JCI editorial policies, JCI review-of-manuscripts guidance, Dual-Journal Submission details for JCI and JCI Insight, Clarivate JCR, SciRev author-reported timing, the JCI first-submission kiosk, the ASCI author account flow, recent JCI disease-mechanism article examples, and Manusights internal analysis of translational medicine manuscripts prepared for JCI, JCI Insight, Nature Medicine, Science Translational Medicine, and specialty clinical journals.

Editorial source synthesis also checked the no-submission-charge statement, required Supporting Data Values file, three suggested reviewers, 200-word abstract requirement, sex-as-biological-variable expectation, and external-review average timing. Source limitations: we did not test a private live JCI submission account for this page; portal and timing guidance is based on public JCI materials, documented author experience, and pre-submission review patterns.

Why this page exists: "Journal of Clinical Investigation submission guide" is a pre-upload strategy query. Authors need to know whether the package is a true JCI disease-mechanism paper before they spend effort on portal fields, cover letter language, or formatting checks.

In our analysis of JCI-targeted manuscripts, the recurring failure pattern is mistaking disease vocabulary for disease mechanism. JCI's public review guidance says papers can be rejected without external review when the study does not significantly advance the field or is not appropriate for JCI readership. That maps directly onto the manuscripts we see: the figures have to make the human-disease argument, not just the title and discussion.

What the JCI process does well: It gives authors a focused physician-scientist editorial screen and, through the JCI/JCI Insight track, a route for papers that are not ultimately JCI-level but may still fit the family.

Where authors still get hurt: The submission guide cannot rescue a paper whose mechanism is descriptive, whose human evidence is decorative, or whose best audience is a specialist disease journal rather than JCI's broad translational readership.

Alternative pages depend on the decision you are making. Use this page for submission strategy. Use JCI submission process for workflow, JCI formatting requirements for upload mechanics, and the JCI journal hub for the broader page family.